Neurocrine Biosciences (NBIX) R&D In Process (2019 - 2025)
Neurocrine Biosciences' R&D In Process history spans 6 years, with the latest figure at $17.0 million for Q4 2025.
- For Q4 2025, R&D In Process rose 466.67% year-over-year to $17.0 million; the TTM value through Dec 2025 reached $17.4 million, up 39.2%, while the annual FY2025 figure was $17.4 million, 39.2% up from the prior year.
- R&D In Process reached $17.0 million in Q4 2025 per NBIX's latest filing, up from $300000.0 in the prior quarter.
- In the past five years, R&D In Process ranged from a high of $143.9 million in Q1 2023 to a low of $100000.0 in Q1 2025.
- Average R&D In Process over 4 years is $27.9 million, with a median of $4.0 million recorded in 2021.
- The largest YoY upside for R&D In Process was 466.67% in 2025 against a maximum downside of 98.33% in 2025.
- A 4-year view of R&D In Process shows it stood at $100.3 million in 2021, then soared by 43.47% to $143.9 million in 2023, then tumbled by 97.92% to $3.0 million in 2024, then skyrocketed by 466.67% to $17.0 million in 2025.
- Per Business Quant, the three most recent readings for NBIX's R&D In Process are $17.0 million (Q4 2025), $300000.0 (Q3 2025), and $100000.0 (Q1 2025).